Unified applications for clinical, regulatory, and quality help
fast-growing start-up
drive greater efficiency and compliance
throughout development
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced that Idorsia Pharmaceuticals Ltd
established an integrated development landscape with Veeva
Development Cloud. With unified applications for clinical,
regulatory, and quality on a single cloud platform, Idorsia now has the
technology foundation to accelerate product innovation and support its
global growth plans.
“With a strong pipeline of innovative new therapies, we needed
cutting-edge cloud technology that could scale as we grow,” said Joseph
Bejjani, CIO at Idorsia. “Our IT strategy had three guiding principles
when it came to product selection – cloud-first, easy-to-use
functionality, and integrated, platform-based solutions. Veeva met all
three objectives within a very tight timeline.”
Idorsia is a fast-growing biopharmaceutical start-up focused on research
and early-stage clinical development. Immediately after its founding,
Idorsia set an aggressive timeline to transition to new clinical
development systems within 12 months.
With Veeva Development Cloud, Idorsia has unified applications to
streamline documents and workflows so teams have a single source of
truth across clinical, regulatory, and quality. This eliminates manual,
duplicative efforts and gives teams consistent information throughout
development. Because Veeva Vault applications have the same modern and
intuitive interface, teams work with greater speed and spend less time
on training.
“Veeva gives us the right technology foundation to manage business
processes, content, and data across the organization,” said Simone
Mechler, associate director clinical & quality systems. “We exceeded our
goal and went live within seven months. All regions and departments now
have a consistent view of the products in development to drive greater
operational efficiency and maintain compliance.”
Idorsia is using or plans to use multiple applications across Veeva
Development Cloud suites, including Vault
eTMF and Vault
CTMS from Vault
Clinical Suite; Vault
Registrations, Vault
Submissions, and Vault
Submissions Publishing from Vault
RIM Suite; and Vault
QMS and Vault
QualityDocs from Vault
Quality Suite.
“Idorsia needed to bring together their applications for clinical,
quality, and regulatory to streamline drug development,” said Rik Van
Mol, vice president, R&D strategy, Europe at Veeva. “Veeva Development
Cloud helps life sciences companies like Idorsia achieve alignment
across headquarters, sites, and countries and increase communication,
collaboration, and compliance across the functions.”
Additional Information
For more about Veeva Development Cloud, visit: veeva.com/VeevaDevelopmentCloud
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 625 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended
April 30, 2018. This is available on the company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180710005256/en/
Veeva Systems
Roger Villareal, 925-264-8885
roger.villareal@veeva.com
or
Lisa
Barbadora, 610-420-3413
pr@veeva.com
Source: Veeva Systems